American Regent v. Sun Pharma: Selenium Injection Patent Suit Consolidated
American Regent, Inc. filed suit against Sun Pharmaceutical Industries in the District of New Jersey asserting US11998565B2 covering selenium injection formulations. Within 128 days, the case was folded into a sweeping 13-defendant consolidated ANDA action — one of the broadest multi-generic pharmaceutical patent battles of 2024.
A 13-front ANDA war: American Regent consolidates selenium IV litigation
On July 16, 2024, American Regent, Inc. filed parallel infringement actions against at least 13 generic pharmaceutical manufacturers in the District of New Jersey, each asserting US11998565B2, which covers parenteral selenium formulations in multiple concentrations including 60 mcg/mL, 600 mcg/10 mL, and 12 mcg/2 mL injectable products. The action against Sun Pharmaceutical Industries, Inc. was assigned Case No. 2:24-cv-07810 and is one strand of what is plainly a coordinated Hatch-Waxman ANDA litigation campaign.
On October 22, 2024, the court issued a consolidation order merging all 13 related actions — including the Sun Pharma docket — into lead case No. 2:24-cv-07791. All future filings are to be made under that caption. This procedural consolidation closed this individual docket on November 21, 2024, but did not resolve the underlying merits. Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Industries Limited remain parties in the consolidated proceeding.
The 128-day interval between filing and consolidation is consistent with efficient ANDA case management practice where a brand manufacturer moves quickly to unify parallel generic challenges before scheduling diverges. The public record is silent on whether any defendant has filed an Answer asserting invalidity or non-infringement, or whether any ANDA paragraph IV certification details have been publicly docketed. The consolidated docket is where substantive litigation will now proceed.
Filing to Case Consolidated in 128 days
128 days — resolved into consolidation faster than median ANDA district court timeline
Case consolidated: what the merger means for Sun Pharma and the litigation
Consolidation under Rule 42: one docket, 13 defendants
Under Federal Rule of Civil Procedure 42(a), a court may consolidate actions involving common questions of law or fact. Here, all 13 defendants face the same patent — US11998565B2 — and substantially similar ANDA-based infringement allegations. Consolidation into lead docket 24-7791 streamlines scheduling, discovery, and claim construction, but does not merge parties’ substantive rights or defenses.
Rule 42(a) consolidationAmerican Regent gains litigation efficiency across all 13 fronts
Consolidation typically favours the plaintiff in multi-defendant ANDA cases: a single Markman hearing and unified discovery schedule reduce cost and prevent inconsistent claim construction rulings. American Regent can now pursue a single coordinated strategy against the entire field of generic challengers. The 30-month stay clock under Hatch-Waxman may run differently per defendant depending on individual ANDA filing dates.
Brand plaintiff advantageSun Pharma faces coordinated litigation alongside 12 rival generics
For Sun Pharmaceutical, consolidation means that invalidity and non-infringement arguments will be litigated in a shared forum alongside competing generics. While defendants may align on invalidity strategy, they may diverge on infringement positions depending on their specific ANDA formulations. Sun Pharma’s exposure continues; the individual docket closing does not signal resolution in its favour.
Merits remain openBroad ANDA consolidations signal growing IV nutrition patent enforcement
The scale of this consolidation — 13 generic defendants facing a single parenteral selenium patent — suggests American Regent views US11998565B2 as a portfolio cornerstone worth defending broadly. For manufacturers developing IV micronutrient formulations, this litigation signals heightened enforcement risk in the selenium injection space and warrants proactive FTO assessment against ARI’s patent estate.
IV nutrition enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical manufacturer and IV nutrient specialist — holder of US11998565B2Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Sun Pharmaceutical Industries, Inc. — US subsidiary of global generic drug manufacturer Sun PharmaSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Gregory D. Miller | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | MARCUS O. TUBIN | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy P. Gonzalez | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Rivkin Radler LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural rather than substantive — it reflects judicial efficiency in managing parallel Hatch-Waxman actions sharing a common patent and similar infringement theories, not any merits determination. The order’s enumeration of all 13 co-pending actions underscores the breadth of American Regent’s enforcement campaign. No liability finding, no validity ruling, and no settlement terms are recorded. The operative litigation now proceeds under docket 24-7791, where claim construction and merits rulings will carry determinative weight for all defendants including Sun Pharma.
US11998565B2 — Parenteral selenium injection formulations
US11998565B2, filed under application number US18/124391, protects parenteral selenium formulations delivered intravenously across multiple concentration presentations: 600 mcg selenium per 10 mL (60 mcg/mL), 60 mcg/mL unit-dose, and 12 mcg per 2 mL lower-concentration vials. Selenium is an essential trace element included in total parenteral nutrition (TPN) protocols; the patent likely covers formulation-specific aspects such as stabilisation chemistry, pH control, or concentration ratios that distinguish ARI’s commercial product from prior art injectable selenium.
The strategic significance of US11998565B2 lies in its apparent ability to support simultaneous enforcement against 13 generic manufacturers — a breadth that suggests commercially broad claim scope covering standard concentration presentations used across the IV nutrition market. For any pharmaceutical company developing or reformulating selenium injection products, this patent represents a material freedom-to-operate obstacle. The consolidated litigation will produce a Markman ruling that defines the enforceable claim boundaries, making the New Jersey docket a critical monitoring target through 2025–2027.
Should you run an FTO against US11998565B2?
Any manufacturer, contract development organisation, or hospital pharmacy compounding IV selenium products — particularly at the 60 mcg/mL, 600 mcg/10 mL, or 12 mcg/2 mL concentrations — should treat US11998565B2 as a live enforcement risk. The fact that American Regent simultaneously asserted this patent against 13 separate ANDA filers suggests confidence in the patent’s claim breadth. R&D teams reformulating parenteral selenium or developing novel trace element combination products should conduct FTO analysis before filing an ANDA or commencing commercial manufacture.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map product formulation parameters against the asserted claims of US11998565B2, identify prior art relevant to invalidity arguments being pursued in the consolidated litigation, and monitor continuation applications in the US18/124391 family for newly granted claims. With 13 defendants now litigating in parallel, Eureka’s litigation monitoring tools can surface IPR petitions, claim construction briefs, and expert disclosures as they become public — giving your team a real-time picture of how the patent’s scope is being contested.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: IV nutrition and parenteral formulation disputes
Explore consolidated ANDA patent infringement cases in New Jersey involving parenteral nutrition, trace element formulations, and Hatch-Waxman enforcement by branded IV drug manufacturers.
What this case signals for the IV pharmaceutical patent landscape
A 13-defendant ANDA consolidation in New Jersey is a rare show of enforcement force. Generic entrants in the parenteral nutrition space should take note.
Coordinate or compete: generic defendants face a strategic dilemma in consolidation
Consolidation forces Sun Pharma and 12 co-defendants to decide how much to align their invalidity strategies. Shared prior art arguments can reduce cost, but divergent ANDA formulations may require independent non-infringement positions. IP teams should map their specific product against the asserted claims of US11998565B2 before any joint defense agreement is finalised.
The 30-month stay: timing is everything for generic selenium market entry
In Hatch-Waxman litigation, a timely-filed infringement suit triggers a 30-month stay of FDA ANDA approval. With filings dating to July 2024, the stay window is likely to extend into early 2027 for most defendants. Generic manufacturers should model launch timelines against both the stay expiry and potential at-risk launch scenarios if invalidity arguments advance.
American v Sun — key questions answered
The case was consolidated with 12 related ANDA actions into lead docket 2:24-cv-07791 in the District of New Jersey. American Regent asserted US11998565B2 covering selenium injection formulations against Sun Pharmaceutical Industries, Inc. The individual docket closed November 21, 2024 after a consolidation order was entered on October 22, 2024. No merits ruling was issued.
American Regent asserted US11998565B2, filed under application US18/124391, covering parenteral selenium injection formulations. The products at issue include selenium concentrations of 60 mcg/mL, 600 mcg/10 mL, and 12 mcg/2 mL — standard intravenous trace element presentations used in total parenteral nutrition protocols.
The court consolidated 13 parallel ANDA infringement actions filed by American Regent against different generic manufacturers because they all involve the same patent and substantially similar legal questions. Consolidation under Rule 42(a) means all defendants litigate in a single coordinated proceeding under docket 24-7791. It does not resolve the underlying patent infringement or invalidity issues.
The individual docket 2:24-cv-07810 is closed, but Sun Pharmaceutical Industries remains a defendant in the consolidated action under lead docket 2:24-cv-07791. The underlying patent infringement claims are unresolved. Practitioners should monitor the lead docket for scheduling orders, claim construction proceedings, and any settlement or IPR developments.
The consolidated action includes Accord Healthcare, Aspiro Pharma, Cipla USA and Cipla Limited, Dr. Reddy’s Laboratories, Eugia Pharma Specialities and Eugia US LLC, Gland Pharma, Hikma Pharmaceuticals USA, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics entities, Sun Pharmaceutical Industries, Xiromed LLC and Xiromed Pharma España, and Zydus Pharmaceuticals — 13 actions in total.
PatSnap Eureka searches patents and litigation data to answer instantly.